Deciphera Pharmaceuticals IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Deciphera Pharmaceuticals | DCPH - NASDAQ |
$15.00-$17.00 | $17.00 | $20.05 | 7.5 million | 9/28/2017 |
| J.P. Morgan, Piper Jaffray | ||||||
Co-Manager(s): JMP Securities, Nomura | ||||||
| Health Care | ||||||
Filing(s): Filed 2017-09-01 Terms Added 2017-09-18 | ||||||
Deciphera Pharmaceuticals Quote & Chart - Click for current quote - DCPH
IPO Boutique aggregates information on public companies and private companies, such as "DCPH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Deciphera Pharmaceuticals (adapted from Deciphera Pharmaceuticals prospectus):
They are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company developing new drugs to improve the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of many cancer therapies.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "DCPH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.